GervanoRA Added Inflammatory Bowel Disease Pipeline Analysis - 2018 Report to its Report Store

GervanoRA Data Services has released its latest pipeline analysis report, “Inflammatory Bowel Disease Analysis (IBD) - 2018”. The report includes complete analysis of the pipeline molecules under development used for the treatment of IBD. Report helps emerging companies to understand the strong competitor strategies through its key company profiles and SWOT analysis. Elaborated report information assist clients in understanding the current scenarios in drug development and help in development and design pipeline based in-licensing and out-licensing strategies. The Universities and Institutes added to the report are expected to play a vital role in the market growth. Apart from this, the discontinued and dormant projects poise clarity for the clients.
Required free sample report (PDF)?

https://www.gervanora.com/request-for-sample-report/

IBD Overview
IBD is a collective term for two disease conditions – Crohn’s disease and Ulcerative Colitis. It is caused by a dysregulation of the immune system inducing the production of proinflammatory cytokines and adhesion molecules. This results in the chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract and may lead to ulceration, abscesses and strictures in the bowel.
Report Highlights,
 We expect that the IBD population in the US will grow from 3.1 million in 2016 to 7.9 million in 2025 at a growth rate of 11%.
 There are total 203 molecules in pipeline (Company Molecules 180, University & Institute Molecules 23) in different phases of development.
 According to GervanoRA’s analytics, there were around 99 deals happened since 2010. Among these, there are two mergers, five acquisitions, 47 collaboration agreements, 41 licensing agreements, 3 alliance agreements and four termination agreements.
 As per GervanoRA’s timeline estimations, nine drug candidates are expected to receive approvals in the coming two years. 4 drug candidates will receive regulatory approvals in the year 2019 and five will receive in the year 2020.
Report Coverage:
 Key Pipeline Events
 Drug Pipeline Analysis by Stage of Development, Geography, RoA, MoA, Drug Class, and Drug developments by Companies, Universities and Institutes.
 Disease Overview
 Epidemiology and Epidemiology Forecast
 Deals Activities
 Total Drug Approvals for the Treatment of therapeutics (From 2010)
 Estimated Drug Approval Timelines for all Pipeline Drugs
 Clinical Trials Summary
 Terminated and Discontinued Drugs Projects
 Current and Future Competitive Landscape of Companies
 Key Companies with Drug Profiles and Drug Milestones
 Key Companies SWOT Analysis
 Emerging Companies with Profiles
 Universities and Institutes with Drugs in Pipeline

About GervanoRA
GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.
At GervanoRA Data Services, we're playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.
For more details, please visit our website: www.gervanora.com
Connect with us on LinkedIn @ https://in.linkedin.com/company/gervanora-data-services-llp

GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports and consulting services, based in Goa, India. GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.
At GervanoRA Data Services, we're playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations (KOLs) to garner valuable key insights.

GervanoRA Data Services LLP
Goa IT Innovation Center
Goa Chamber of Commerce and Industry Bldg.
South Goa, Goa
INDIA
403722.

India (Head Office)
Mr. Ramu Jadhav
GervanoRA Data
Services LLP
Verna, Goa - 403722
India
sales@gervanora.com
Ph. No. +91(0)832-2783283

This release was published on openPR.